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ABSTRACT
Objective: The objectives of this study were to
develop a coronary heart disease (CHD) risk model
among the Korean Heart Study (KHS) population and
compare it with the Framingham CHD risk score.
Design: A prospective cohort study within a national
insurance system.
Setting: 18 health promotion centres nationwide
between 1996 and 2001 in Korea.
Participants: 268 315 Koreans between the ages of
30 and 74 years without CHD at baseline.
Outcome measure: Non-fatal or fatal CHD events
between 1997 and 2011. During an 11.6-year median
follow-up, 2596 CHD events (1903 non-fatal and 693
fatal) occurred in the cohort. The optimal CHD model
was created by adding high-density lipoprotein (HDL)-
cholesterol, low-density lipoprotein (LDL)-cholesterol
and triglycerides to the basic CHD model, evaluating
using the area under the receiver operating
characteristic curve (ROC) and continuous net
reclassification index (NRI).
Results: The optimal CHD models for men and
women included HDL-cholesterol (NRI=0.284) and
triglycerides (NRI=0.207) from the basic CHD model,
respectively. The discrimination using the CHD model
in the Korean cohort was high: the areas under ROC
were 0.764 (95% CI 0.752 to 0.774) for men and
0.815 (95% CI 0.795 to 0.835) for women. The
Framingham risk function predicted 3–6 times as many
CHD events than observed. Recalibration of the
Framingham function using the mean values of risk
factors and mean CHD incidence rates of the KHS
cohort substantially improved the performance of the
Framingham functions in the KHS cohort.
Conclusions: The present study provides the first
evidence that the Framingham risk function
overestimates the risk of CHD in the Korean population
where CHD incidence is low. The Korean CHD risk
model is well-calculated alternations which can be
used to predict an individual’s risk of CHD and
provides a useful guide to identify the groups at high
risk for CHD among Koreans.
INTRODUCTION
In 2008, cardiovascular disease (CVD)
accounted for 30% of total global deaths,
while 80% of CVD deaths occurred in low-
income and middle-income countries. Of
these deaths, an estimated 7.3 million were
due to coronary heart disease (CHD) and
6.2 million were due to stroke.1 In Korea,
CVD is now one of the leading preventable
causes of death in Korea, causing 22% of all
deaths in 2011.2
CHD risk scores, which utilise data on mul-
tiple risk factors, are ideal for making
rational decisions regarding the distribution
of scarce health service resources. The
Framingham CHD Risk Score (FRS), devel-
oped in a middle-class population in
Strengths and limitations of this study
▪ Coronary risk scores, which utilise data on mul-
tiple risk factors, are ideal for making rational
decisions regarding the distribution of scarce
health service resources. The Framingham risk
score overestimates the coronary risk in other
populations, such as contemporary populations
in Europe.
▪ There are no data on whether the Framingham
risk score overestimates the coronary risk in
Korea.
▪ Fatal and non-fatal (hospitalised) events among
the study cohort were identified from insurance
claims which were reported to the National
Health Insurance System between the date of
examination and 31 December 2011, giving a
median follow-up of 11.6 years.
▪ This is an unusually large study with over
200 000 participants.
▪ The limitations of this study include possible
measurement errors and the non-random sample
used.
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Massachusetts, is the most commonly used CHD risk
score worldwide. However, in recent years, several investi-
gators have demonstrated that the FRS overestimates the
coronary risk in other populations, such as contempor-
ary populations in Europe3–5 and Asia,6 including
Korea,7 while others have suggested that additional risk
factors may add to the predictability of those included in
the FRS.8–10 Although some studies have investigated
this issue in Asian populations,8 9 none had a follow-up
of over 10 years.
To date, no national CHD risk score has been devel-
oped for Korea, despite the existence of some very large
cohort studies with the potential to produce more reli-
able estimates of risk associations than have previously
been possible.
The objectives of this study were, thus, to evaluate the
applicability of the Framingham risk function11 in the
Korean Heart Study (KHS) population, and to develop a
Korean CHD risk score.
METHOD
Study population
KHS included 430 920 individuals (266 782 men and
164 138 women) who had voluntarily undergone private
health examinations in 18 centres located in the capital
and six provinces in South Korea between 1996 and
2004. A full description of KHS has been previously
published.12 13
To develop a 10-year CHD risk prediction model, the
baseline period used for this study was between 1996
and 2001; however, since we have followed them until
December 2011 this gives at least 10 years of potential
follow-up for everyone included (ﬁgure 1). Sixteen thou-
sand ﬁve hundred and seventy-eight participants who
reported of having cancer, liver disease, CVD or a
respiratory disease at, or prior to, the initial visit were
excluded. Also, 5408 participants with missing informa-
tion on blood pressure, total serum cholesterol, fasting
serum glucose, smoking status or body mass index
(BMI), or who had an extremely low BMI (<16 kg/m2)
or height (≤1.30 m) were excluded. The ﬁnal study par-
ticipants were 268 315 individuals.
Data collection
Data ﬁles were collected from centres that maintained
electronic databases, and manual data coding was per-
formed by trained personnel for data collected from
centres that kept paper records. Smoking habits
(current, former or never smoking) was ascertained
from the questionnaires. Either registered nurses or
blood pressure technicians measured blood pressure
using a standard mercury sphygmomanometer. For clin-
ical chemistry assays, serum was separated from periph-
eral venous blood samples that were obtained from each
participant after 12 h of fasting and was stored at −70°C.
Biomarkers, such as fasting glucose and lipid proﬁles,
were measured using the Histachi-7600 analyser (Hitachi
Ltd, Tokyo, Japan). Details on quality control were pub-
lished previously.12
In 2006, the Korean Association of Quality Assurance
for Clinical Pathology conducted a nationwide study of
interlaboratory agreement, and the Department of
Clinical Pathology at the Asan Medical Center was in
charge of the analysis. After receiving written permis-
sion, we reviewed interlaboratory correlations for the
participating centres. The interlaboratory correlation
coefﬁcients for all measured variables exceeded 0.95.12
Outcome variables
Fatal and non-fatal (hospitalised) events among the
study cohort were identiﬁed from insurance claims
which were reported to the National Health Insurance
System (NHIS) between the date of examination and 31
December 2011, giving a median follow-up of 11.6 years.
Since NHIS is a national organisation covering all of
Korea’s population, this should provide a complete
event ascertainment.
‘Hard’ CHD events, comprising acute myocardial
infarction, sudden death and other coronary deaths,
were included in our study outcome variable.11 We ascer-
tained non-fatal CHD events, deﬁned according to the
International Classiﬁcation of Diseases 10th Revision
(acute myocardial infarction, code I21), from health
insurance claims data from the NHIS. For fatal CHD
events, deaths from death records were collected. Death
certiﬁcates from the National Statistical Ofﬁce were
identiﬁed via identiﬁcation numbers, which are assigned
to citizens at birth.
A validation study was conducted by 20 internists from
the Korean Society of Cardiology in 2009.14 For the par-
ticipants who provided written permission for the use of
their personal information, 673 CHD events between
1994 and 2007 were conﬁrmed with individual hospital
medical records, showing that 73% of designated myo-
cardial infarctions were valid. The validation study was
updated in 2013 with a value of 93%.15 The validation
study on mortality data has not been conducted.Figure 1 Defining the study population.
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Statistical analysis
To develop the risk score, an a priori decision was made
to emulate the most commonly used version of the
FRS11 as far as possible. Thus, age, blood pressure, total
and high-density lipoprotein-cholesterol (HDL-C), dia-
betes and smoking were considered for inclusion in the
Korean CHD risk score (KRS). Furthermore, blood pres-
sure, total and HDL-C were analysed in the same ordinal
groups as in FRS, except that blood pressure was
grouped according to the most recent (7th) guidelines
of the Joint National Committee on Hypertension.16
Contemporary guidelines17 were used to deﬁne diabetes
as self-reported or fasting glucose>=126 mg/dL. In add-
ition, triglycerides and low-density lipoprotein
(LDL)-cholesterol were considered for inclusion in the
Korean risk score, in place of HDL-C, as was an exten-
sion of the deﬁnition of smoking status to include
former smoking. Another a priori decision was to
develop separate risk models for men and women,
where, unlike the FRS, the same variables were to be
used for each sex. This is thought to be the most sens-
ible for practical applications.
To decide on what factors should enter the risk score,
Cox proportional hazards regression models were ﬁtted
ﬁrst to a basic set of classical risk factors: age, blood pres-
sure, total cholesterol (TC), smoking and diabetes.
Further models added, one-at-a-time, were HDL-C,
LDL-cholesterol and triglycerides to this basic set. The
ﬁnal model was prespeciﬁed to be that with the best dis-
crimination and risk classiﬁcation of the four, averaged
across the sexes. Discrimination was assessed by the c-
statistic for survival data18 19 and other models were
compared, for risk classiﬁcation, with the basic model
using the continuous form of the net reclassiﬁcation
index (NRI) for 10-year risk of CHD.
From the ﬁnal model, the KRS was derived using
standard methods.19 Its calibration was tested by dividing
participants, within each sex, into tenths of predicted
risk and using the Hosmer-Lemeshow, calibration and
reclassiﬁcation were carried out after splitting the data
randomly into 50% development and 50% validation
samples.20
Comparison with the Framingham score
We compared the regression coefﬁcients from a Cox
proportional hazard model, ﬁtted to the KHS, with the
same variables as in the FRS and the regression coefﬁ-
cients in the published account of the FRS11 using Wald
tests. We recalibrated Framingham to the KHS popula-
tion19 and compared this to the KRS. All analyses were
conducted using SAS, V.9.1.2 (SAS Institute Inc, Cary,
North California, USA).
RESULTS
Baseline risk factors and CHD incidence rates
After excluding participants with missing values for any
of the FRS risk factors, 268 315 individuals (164 005
men and 104 310 women) were included in these ana-
lyses (table 1). These were largely middle aged at enrol-
ment (mean age 45.8 years in men and 47.6 years in
women). Those excluded due to missing values did not
differ from those included, by age and sex. The mean
levels of BMI and LDL-cholesterol were similar in both
sexes. However, smoking was prevalent in men but
uncommon in women. Similar prevalence rates for high
TC and LDL-cholesterol were observed in men and
women. The prevalence of reduced HDL-C and diabetes
was higher in men than in women (table 2).
During an 11.6-year median follow-up, 2596 CHD
events (1903 non-fatal and 693 fatal) occurred in the
cohort. The average 10-year risk for CHD was 1.03% for
men and 0.40% for women. Summary statistics of
person-years of follow-up and CHD events by baseline
risk factor level, and overall, within sex, are shown in
table 2.
Tables 3 (men) and 4 (women) show the HR for each
level of each prognostic factor, compared to its refer-
ence. As expected, in the 10-year predictions of CHD,
all ﬁve predictors in the basic model (age, blood pres-
sure, TC, smoking and diabetes) were statistically signiﬁ-
cant in both men and women. Models 1, 2 and 3 added
HDL-C, LDL-cholesterol and triglycerides, respectively,
to the basic model. Among these models, model 1 was
the best discriminating model (area under the curve
(AUC)=0.764) for men and also the model with best
reclassiﬁcation of risk (NRI=0.284) compared with the
Table 1 Baseline characteristic of study participants,
1996–2001, the Korean Heart Study
Men Women
N 164 005 104 310
Mean±SD Mean±SD
Age, years 45.8±9.4 47.6±10.0
Body mass index, kg/m2 23.8±2.8 23.2± 3.1
Systolic blood pressure, mm Hg 123.3±16.7 121.0±19.6
Diastolic blood pressure, mm Hg 78.3±11.6 75.3±11.8
Total cholesterol, mg/dL 194.5±34.8 195.1±37.4
HDL-cholesterol, mg/dL 47.9±10.6 54.5±12.7
LDL-cholesterol, mg/dL 118.4±32.2 118.9±33.6
Triglyceride, mg/dL 148.2±87.1 113.3±67.5
Fasting glucose, mg/dL 97.1±24.2 93.6±20.6
% %
Smoking status
Ex-smoker 23.0 4.0
Current smoker 53.0 5.1
Diabetes* 8.4 6.0
Medication 1.9 1.6
Hypertension† 28.6 24.7
Medication 4.4 5.3
*Diabetes was defined as fasting serum glucose greater than
126 mg/dL or diabetic treatment history.
†Hypertension was defined as systolic blood pressure greater
than 140 mm Hg or diastolic blood pressure greater than
90 mm Hg or medication.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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basic model (to which it was superior). For women,
model 3 was the best model on both criteria
(AUC=0.815 and NRI=0.207). The second best model
that reﬂects the women is model 1 (AUC=0.812 and
NRI=0.177). The KRS was adopted from model 1 for
both the sexes. The KRS algorithm is given in online
supplementary appendix A.
Comparison of the Framingham and the Korean risk
equations
Compared with the HRs from the KHS using the same
variables, there were no big differences with the
published HRs for Framingham, with the exception of
LDL-cholesterol (table 5). The FRS overestimated,
overall by a factor of six, the number of CHD events
actually observed in the KHS. Figure 2 shows the agree-
ment between the original and recalibrated
Framingham function and the KRS in the KHS popula-
tion. The KRS and recalibrated FRS are clearly in close
agreement, as would be anticipated from table 5.
DISCUSSION
The objectives of this study were (1) to develop a Korean
CHD model; (2) to evaluate the ability of the FRS to
Table 2 Baseline risk factors, person-years of follow-up and CHD events in men and women in the Korean Heart Study,
aged 30–74 years, 1996–2011*
Men (n=164 005) Women (n=104 310)
Person-years
of follow-up
Hard
CHD
events†
Incidence
per 100 000
PY¶
Person-years
of follow-up
Hard
CHD
events†
Incidence
per 100 000
PY¶
Total† 1 961 999 2086 121.1 1 281 102 510 52.1
Blood pressure
Normal 683 826 468 92.4 602 146 91 25.9
Prehypertension 798 672 774 116.7 415 032 167 48.5
Stage-1
hypertension
347 579 539 149.0 178 672 133 61.8
Stage-2
hypertension
131 922 305 194.8 85 253 119 94.2
Total cholesterol, mg/dL
<160 293 873 173 81.4 213 533 32 17.1
160–199 854 406 698 99.8 533 694 145 45.7
200–239 619 971 810 139.3 382 484 200 53.4
240–279 166 830 316 185.2 123 315 93 64.1
≥280 26 918 89 355.8 28 076 40 118.7
HDL-cholesterol, mg/dL
<35 157 245 292 193.7 42 652 28 59.6
35–44 618 462 768 140.5 242 097 128 63.5
45–49 438 772 427 116.5 205 596 107 71.2
50–59 523 426 429 99.0 390 158 144 45.0
≥60 224 094 170 80.7 400 598 103 36.6
LDL-cholesterol, mg/dL
<100 562 674 372 82.7 385 816 75 42.2
100–129 733 988 661 106.6 463 200 158 46.2
130–149 353 968 447 138.9 217 960 113 54.7
≥150 311 369 606 195.2 214 126 164 66.5
TG, mg/dL
<100 621 804 441 87.5 685 429 134 35.9
100–149 583 391 609 115.7 332 866 142 47.6
150–199 357 517 464 149.0 143 896 110 65.7
200–249 189 163 269 148.5 62 412 70 99.6
≥250 210 123 303 169.0 56 499 54 83.0
Smoking status
Ex-smoker 454 230 448 94.2 51 928 24 53.8
Current smoker 1 038 830 1271 155.0 64 612 38 88.0
Diabetes 162 348 399 217.7 75 840 98 96.1
SI conversions: to convert HDL-C and TG to mmol/L, multiply by 0.0259.
*Participants with risk factor at baseline (1996–2001).
†Mean ages of Korean were 45.8 years in men and 47.6 years in women, respectively.
¶Incidences were standardized to the age distribution in the 2005 Korean population.
CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PY, person-years; TG, triglycerides.
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predict the 10-year CHD risk in the Korean population.
Over 2700 ﬁrst CHD events occurred in this cohort
of over 268 000 Koreans in 11.6 years. The KRS was
developed based on these data. When compared with
the actual CHD cases, the KRS performed well, but
not substantially better than a recalibrated version of
the FRS.
Estimation of absolute risk required for treatment and
for prevention of CHD commonly relies on prediction
models developed from the experience of prospective
cohort studies.8–10 21 Although prediction algorithms
developed by the Framingham investigators have been
widely adopted to formulate clinical guidelines in the
USA and elsewhere,21 the Framingham functions have
overestimated the CHD risk in some populations,
leading to a concern that it may not be appropriate
to other populations.3–6 8 In our study, the FRS also over-
estimated the risk of CHD in the Korean population,
where CHD incidence is relatively low. Another factor of
relevance is the inclusion of softer CHD end points
in the derivation of the FRS than we used in deriving
the KHS.
Several studies3 6 have examined CHD events in the
Framingham Heart Study (FHS). Due to problems
anticipated risk Framingham, Ahn et al7 previously sug-
gested the need for Korean guidelines for the manage-
ment of CHD to avoid artiﬁcial inﬂation of costs in
primary prevention.
Table 3 HRs for CHD risk factors in men in the Korean Heart Study, aged 30–74, 1996–2011
Basic model Model 1 Model 2 Model 3
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age 1.13 (1.09 to 1.18) 1.13 (1.08 to 1.18) 1.13 (1.08 to 1.18) 1.13 (1.08 to 1.18)
Blood pressure
Normal 1.00 1.00 1.00 1.00
Prehypertension 1.30 (1.16 to 1.46) 1.29 (1.15 to 1.45) 1.32 (1.17 to 1.48) 1.28 (1.14 to 1.43)
Stage-1 hypertension 1.74 (1.53 to 1.97) 1.72 (1.52 to 1.96) 1.78 (1.57 to 2.02) 1.68 (1.48 to 1.91)
Stage-2 hypertension 2.22 (1.91 to 2.57) 2.20 (1.90 to 2.56) 2.28 (1.97 to 2.65) 2.13 (1.84 to 2.48)
Total cholesterol, mg/dL
<160 1.00 1.00 1.00 1.00
160–199 1.26 (1.07 to 1.49) 1.34 (1.14 to 1.59) 1.09 (0.90 to 1.32) 1.21 (1.02 to 1.43)
200–239 1.81 (1.53 to 2.13) 2.02 (1.71 to 2.38) 1.23 (0.99 to 1.53) 1.67 (1.42 to 1.98)
240–279 2.42 (2.01 to 2.92) 2.77 (2.30 to 3.34) 1.34 (1.04 to 1.73) 2.19 (1.81 to 2.65)
≥280 3.79 (2.93 to 4.91) 4.45 (3.44 to 5.76) 2.02 (1.47 to 2.77) 3.37 (2.59 to 4.38)
Smoking
Never 1.00 1.00 1.00 1.00
Former 1.01 (0.88 to 1.16) 1.02 (0.89 to 1.17) 1.02 (0.89 to 1.17) 1.00 (0.87 to 1.15)
Current 1.93 (1.72 to 2.17) 1.86 (1.65 to 2.09) 1.96 (1.75 to 2.21) 1.87 (1.66 to 2.11)
Diabetes
No 1.00 1.00 1.00 1.00
Yes 1.69 (1.51 to 1.89) 1.63 (1.46 to 1.82) 1.72 (1.53 to 1.92) 1.65 (1.48 to 1.85)
HDL-cholesterol, mg/dL
<35 1.00
35–44 0.66 (0.57 to 0.75)
45–49 0.56 (0.48 to 0.65)
50–59 0.45 (0.39 to 0.52)
≥60 0.34 (0.28 to 0.41)
LDL-cholesterol, mg/dL
<100 1.00
100–129 1.23 (1.06 to 1.43)
130–149 1.50 (1.25 to 1.80)
≥150 1.97 (1.61 to 2.40)
Triglycerides, mg/dL
<100 1.00
100–149 1.21 (1.07 to 1.37)
150–199 1.35 (1.18 to 1.54)
200–249 1.39 (1.19 to 1.63)
≥250 1.30 (1.11 to 1.52)
ROC (95% CI) 0.756 (0.745 to 0.766) 0.764 (0.752 to 0.774) 0.758 (0.747 to 0.769) 0.757 (0.746 to 0.768)
Continuous NRI (95% CI) Referent model 0.284 (0.231 to 0.339) 0.185 (0.124 to 0.246) 0.109 (0.051 to 0.162)
SI conversions: to convert HDL-C and TC to mmol/L, multiply by 0.0259.
CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NRI, net reclassification index; ROC, receiver
operating characteristic; TC, total cholesterol.
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To compare the CHD risk factors in men and women
in the KHS to those in the FHS, the same six variables
that were examined in the FHS paper were analysed—
age (year), blood pressure (mm Hg), TC (mg/dL),
HDL-C (mg/dL), diabetes and smoking. The FHS did
not yield signiﬁcant HDL-C ≥60 mg/dL results for men
(RR, 0.63, 95% CI 0.34 to 1.18) and women (RR, 0.58,
95% CI 0.33 to 1.02).6 21 In Korean men, however, 11%
had HDL-C ≥60 mg/dL (RR, 0.33, 95% CI 0.28 to 0.41),
a 66% (RR, 0.34) decrease in risk compared with KHS
men with HDL-C <35 mg/dL. The considerable reduc-
tion of CHD risk in participants with higher HDL-C
levels reinforces the need for Korean populations to
monitor their cholesterol levels closely.
Hippisley-Cox et al22 also developed, validated and
evaluated a new QRISK model to estimate lifetime risk
of CVD in the UK. This model was made in light of the
emergence of a new cardiovascular risk prediction tool,
which was shown to have greater predictive ability than
the Framingham risk equation.23 Without recalibration
they urge caution in using the FRS to identify high risk
patients in the UK. Recently, the key issue is the extent
of reallocation. Allocation is critically dependent on the
cardiovascular risk score used and its performance in
contemporaneous, ethnically diverse UK populations.24
The strengths of this cohort study include a large
sample size, a wide age range and a nationally representa-
tive sample. The KHS cohort consisted of 268 315
Table 4 HRs for CHD risk factors in women in the Korean Heart Study, aged 30–74, 1996–2011
Basic model Model 1 Model 2 Model 3
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age 1.14 (1.03 to 1.26) 1.13 (1.02 to 1.24) 1.14 (1.03 to 1.26) 1.12 (1.01 to 1.24)
Blood pressure
Normal 1.00 1.00 1.00 1.00
Prehypertension 1.61 (1.24 to 2.09) 1.57 (1.21 to 2.04) 1.61 (1.32 to 2.09) 1.54 (1.19 to 2.01)
Stage-1 hypertension 2.01 (1.52 to 2.66) 1.93 (1.46 to 2.56) 2.01 (1.52 to 2.66) 1.88 (1.42 to 2.50)
Stage-2 hypertension 3.15 (2.35 to 4.21) 3.02 (2.26 to 4.05) 3.15 (2.36 to 4.22) 2.90 (2.17 to 3.89)
Total cholesterol, mg/dL
<160 1.00 1.00 1.00 1.00
160–199 1.17 (0.80 to 1.72) 1.26 (0.86 to 1.86) 1.10 (0.71 to 1.69) 1.12 (0.76 to 1.65)
200–239 1.45 (0.99 to 2.12) 1.62 (1.10 to 2.38) 1.29 (0.79 to 2.10) 1.31 (0.87 to 2.00)
240–279 1.53 (1.01 to 2.31) 1.77 (1.16 to 2.68) 1.36 (0.78 to 2.38) 1.32 (0.87 to 2.00)
≥280 2.38 (1.48 to 3.82) 2.78 (1.72 to 4.50) 2.12 (1.14 to 3.95) 1.96 (1.21 to 3.18)
Smoking
Never 1.00 1.00 1.00 1.00
Former 1.17 (0.78 to 1.77) 1.20 (0.79 to 1.80) 1.17 (0.78 to 1.77) 1.19 (0.79 to 1.80)
Current 2.06 (1.47 to 2.87) 2.00 (1.43 to 2.79) 2.06 (1.48 to 2.88) 1.95 (1.39 to 2.72)
Diabetes
No 1.00 1.00 1.00 1.00
Yes 1.96 (1.57 to 2.45) 1.89 (1.51 to 2.37) 1.96 (1.57 to 2.46) 1.84 (1.47 to 2.30)
HDL-cholesterol, mg/dL
<35 1.00
35–44 0.79 (0.52 to 1.19)
45–49 0.86 (0.56 to 1.31)
50–59 0.66 (0.44 to 1.00)
≥60 0.51 (0.33 to 0.78)
LDL-cholesterol, mg/dL
<100 1.00
100–129 1.11 (0.80 to 1.54)
130–149 1.16 (0.79 to 1.72)
≥150 1.13 (0.74 to 1.74)
Triglyceride, mg/dL
<100 1.00
100–149 1.19 (0.93 to 1.51)
150–199 1.61 (1.23 to 2.09)
200–249 2.13 (1.58 to 2.89)
≥250 1.63 (1.17 to 2.27)
ROC (95% CI) 0.809 (0.789 to 0.829) 0.812 (0.792 to 0.833) 0.809 (0.789 to 0.829) 0.815 (0.795 to 0.835)
Continuous NRI (95% CI) Referent model 0.177 (0.043 to 0.313) 0.160 (0.019 to 0.295) 0.207 (0.087 to 0.336)
SI conversions: to convert HDL-C and TC to mmol/L, multiply by 0.0259.
CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NRI, net reclassification index; ROC, receiver
operating characteristic; TC, total cholesterol.
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participants aged 30–74 years, which was compared to
5251 participants aged 30–74 in the FHS. Examination of
alternative lipid variables, triglycerides and
LDL-cholesterol, and ﬁner classiﬁcation of smoking
habits to include former smokers, strengthens this study.
Moreover, discrimination, calibration and reclassiﬁcation
are all considered here, using contemporary methods.19
The limitations of this study include possible measure-
ment errors. Clinical data from the health promotion
centres were one-time measurements of blood pressure
and medical examinations. Also, participants might have
under-reported the smoking status and alcohol consump-
tion in the self-report questionnaires. In addition, the val-
idation study on mortality data has not been conducted.
In conclusion, we developed a CHD prediction model
for Koreans and compared the estimates from the
model with the actual CHD cases. This new model pro-
vides an accurate prediction of the risk of CHD among
Korean. With the gradual rise in CHD events among
Koreans, the prevention and treatment of CHD risk
factors such as hypertension, hypercholesterolaemia and
diabetes are important public health concerns.
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Figure 2 Agreement between both the original and
recalibrated Framingham risk scores and the Korean risk
score for coronary heart disease, by 10th of the predicted
risks from the Korean risk score.
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